Iteos <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Delisting from Nasdaq Following Merger Completion
iTeos Therapeutics Inc. has announced a significant regulatory development following its merger with Concentra Biosciences, LLC. The company has completed a tender offer and subsequently become a wholly owned subsidiary of Concentra. As part of this transition, iTeos has notified The Nasdaq Stock Market of the merger's consummation and requested the suspension of trading of its shares, effective from August 29, 2025. Additionally, the company intends to delist its shares from Nasdaq and deregister them under the Securities Exchange Act of 1934. This move includes filing a Certification and Notice of Termination of Registration on Form 15, seeking to terminate the shares' registration and suspend reporting obligations under Sections 13 and 15(d) of the Exchange Act. The regulatory changes mark a significant shift in the company's public status post-merger.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iteos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-192031), on August 29, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。